Ventyx reports mixed results in Crohn’s disease trial

SAN DIEGO - Ventyx Biosciences , Inc. (NASDAQ:VTYX), currently trading at $1.71 and identified as undervalued by InvestingPro analysis, shared outcomes from a Phase 2 trial of its drug candidate VTX958, designed to treat Crohn’s disease, which did not meet its primary endpoint but showed promise in other measures. While the company maintains a strong liquidity position with a current ratio of 23.52, the findings presented at the European Crohn’s and Colitis Organisation Congress in Berlin come at a crucial time for the clinical-stage biotech firm.

The trial aimed to assess the efficacy of VTX958, an oral TYK2 inhibitor, in patients with moderate to severe Crohn’s disease. Despite not achieving the primary goal of significant change in the Crohn’s Disease Activity Index (CDAI) at Week 12, Ventyx observed a dose-dependent endoscopic response and reductions in inflammatory markers like C-reactive protein and fecal calprotectin. According to InvestingPro data, analyst price targets for VTYX range from $2 to $21, reflecting varied expectations about the company’s pipeline potential.

Raju Mohan, PhD, CEO of Ventyx, expressed confidence in the potential of VTX958, citing the robust endoscopic responses and improvements in inflammatory markers as indicators of the drug’s promise. Silvio Danese, MD, PhD, a gastroenterology professor, also noted the drug’s potential for disease-modifying benefits.

The study involved 109 subjects who received either a placebo or one of two dosages of VTX958 over a 12-week treatment period, followed by a 40-week maintenance phase. Although the primary endpoint was not met, possibly due to an unexpected placebo response, the secondary endpoints revealed positive endoscopic results and biomarker reductions.

Participants on VTX958 showed greater endoscopic response rates and combined endoscopic response and clinical remission compared to those on placebo. Additionally, a higher percentage of VTX958 patients achieved a clinical-biomarker response.

The data from the 52-week long-term extension phase of the trial is still under analysis, which Ventyx believes will inform future development strategies and potential partnership opportunities for VTX958 in treating Crohn’s disease.

Ventyx specializes in developing oral therapies for autoimmune and inflammatory diseases. Its portfolio includes other drug candidates in various stages of clinical development.

This report is based on information provided in a press release statement from Ventyx Biosciences. While the company holds more cash than debt on its balance sheet, InvestingPro analysis indicates rapid cash burn and weak profit margins. For comprehensive insights into VTYX’s financial health and detailed analysis, investors can access the full Pro Research Report, available exclusively to InvestingPro subscribers.

In other recent news, Ventyx Biosciences has made significant strides in its clinical trials. The biopharmaceutical company has initiated Phase 2 trials for its NLRP3 inhibitor portfolio, which targets various inflammatory and neurodegenerative diseases. First dosing in a Phase 2 trial of VTX3232, aimed at treating obesity and cardiometabolic risk factors, has been announced, with results anticipated in the second half of 2025.

A Phase 2 trial for VTX2735 in recurrent pericarditis is also on the horizon, set to commence soon, with topline data expected in the latter half of 2025. Furthermore, Ventyx is underway with a Phase 2 biomarker trial of VTX3232 in early Parkinson’s disease, with results due in the first half of 2025.

The company’s cash reserves, including cash equivalents and marketable securities, totaled $252.9 million as of the end of 2024, projected to fund operations until the second half of 2026. In addition to the NLRP3 inhibitors, Ventyx has also provided updates on its inflammatory bowel disease portfolio, including tamuzimod (VTX002) and VTX958, both of which have completed Phase 2 clinical trials. These are the recent developments in the company’s efforts to advance its therapeutic portfolio.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.